Stop press … Dendreon Provenge conference call

According to a media release from Dendreon earlier this evening, there will be a conference call at 9 am EST/6 am PT tomorrow morning (Tuesday, April 14) at which the company will “review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE® (sipuleucel-T), the Company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer.”

To listen to this conference call, you may dial in to 1-877-419-6594 (domestic) or +1-719-325-4855 (international) or you can watch a webcast via the Dendreon web site.

%d bloggers like this: